Ex parte GAULL - Page 8




          Appeal No. 95-3337                                                          
          Application No. 07/759,100                                                  


          (paragraph bridging pages 6 and 7 of specification), I am of                
          the opinion that one of ordinary skill in the art would have                
          found it prima facie obvious to include the recombinant                     
          lysozyme of EPO '634 in a synthetic human infant formula.  In               
          my view, incorporating recombinant lysozyme in an artificial                
          human infant formula would have been an obvious use of the                  
          genetically engineered lysozyme disclosed by EPO '634.  I find              
          this particularly so since appellant's specification states at              
          page 6 that "it has even been proposed to employ human                      
          lysozyme derived from human milk to enrich synthetic cow milk               
          based formula so that the lysozyme-enriched cow-based infant                
          formula more closely approximates human milk with respect to                
          lysozyme content and activity. . . ."  I agree with the                     
          examiner that one of ordinary skill in the art would have had               
          a reasonable expectation that recombinant lysozyme is free of               
          human viruses.  Indeed, appellant acknowledges at page 6 of                 
          his specification that contamination with human virus "is not               
          a reasonable possibility when the human milk proteins,                      
          including the so-called host resistance factors, are produced               
          as recombinant human milk proteins or recombinant host                      
          resistant factors employing genetic engineering techniques."                
                                          8                                           





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  Next 

Last modified: November 3, 2007